Streetbeat News

OKYO

OKYO Pharma Limited

https://www.okyopharma.com

Industry

Biotechnology

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on OKYO Pharma (NASDAQ:OKYO) and increased the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 3:05 pm

OKYO Pharma's shares surged following the announcement that its OK-101 drug achieved statistical significance in treating multiple signs and symptoms of dry eye disease during its Phase 2 trial.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 11:12 am

In Friday's after-market session, several healthcare stocks showed significant movement. Ainos (AIMD) led the gainers with a 54.3% increase, while Healthcare Triangle (HCTI) led the losers with an 8.1% decrease. Other notable movers included Aadi Bioscience (AADI), Taysha Gene Therapies (TSHA), and Biolase (BIOL).

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 9:32 pm

In Monday's pre-market session, several healthcare stocks showed significant movement. SeaStar Medical Holding (ICU) led the gainers with a 27.9% increase, while AN2 Therapeutics (ANTX) experienced the largest drop among the losers, declining by 69%. Other notable movers included Aesthetic Medical Intl (AIH), Virios Therapeutics (VIRI), and Exscientia (EXAI) with substantial gains, and Larimar Therapeutics (LRMR) and Invivyd (IVVD) with notable losses.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 1:06 pm

In Friday's intraday session, several health care stocks experienced significant movements. Notably, Intelligent Bio Solutions (INBS) surged by 219.4%, while Synlogic (SYBX) dropped by 46.8%. Other companies like NanoString Technologies (NSTG), TC BioPharm (TCBP), and Arcutis Biotherapeutics (ARQT) also saw notable price changes. These movements reflect a dynamic day in the health care sector, with both substantial gains and losses.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 5:31 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. NanoString Technologies, TC BioPharm, OKYO Pharma, Corvus Pharma, CytoMed Therapeutics, and Ontrak were among the gainers, with NanoString Technologies leading with a 26.9% increase. Conversely, Synlogic, BioXcel Therapeutics, Evoke Pharma, Syra Health, Inspire Veterinary, and Design Therapeutics were the losers, with Synlogic experiencing the largest drop of 52.2%.

Portfolio Pulse from Benzinga Insights

February 09, 2024 | 1:06 pm

The FDA has approved Okyo Pharma's OK-101 as its first investigational new drug for treating neuropathic corneal pain. The clinical trial is scheduled to start in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 12:02 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Syra Health (SYRA) led the gainers with a 21.2% increase, while Synaptogenix (SNPX) saw the largest decline among the losers with an 8.5% drop. Other notable movers included Universe Pharmaceuticals (UPC), MaxCyte (MXCT), Elevation Oncology (ELEV), and BrainsWay (BWAY) with gains, and OKYO Pharma (OKYO), LumiraDx (LMDX), Soligenix (SNGX), 180 Life Sciences (ATNF), and Vigil Neuroscience (VIGL) with losses.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 9:31 pm

HC Wainwright & Co. analyst Yi Chen has reaffirmed a Buy rating on OKYO Pharma (NASDAQ:OKYO) and increased the price target from $4 to $5.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:18 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on OKYO Pharma (NASDAQ:OKYO) and maintained a price target of $4. The reaffirmation of the Buy rating and price target suggests a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 11:49 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.